Evidence map›Paper›PMID 33663531›Full record

ArticleVirology journal2021

Construction of a recombinant avipoxvirus expressing the env gene of Zika virus as a novel putative preventive vaccine.

Carlo Zanotto, Francesca Paolini, Antonia Radaelli, Carlo De Giuli Morghen

Abstract read
In one paragraph

Article in Virology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Carlo ZanottoLaboratory of Molecular Virology and Recombinant Vaccine Development, Department of Medical Biotechnologies and Translational Medicine, University of Milan, Via Vanvitelli 32, 20129, Milan, Italy.
Francesca PaoliniHPV-UNIT, Laboratory of Virology, Regina Elena National Cancer Institute, Via delle Messi d'Oro, 156, 00158, Rome, Italy.
Antonia Radaelli *Laboratory of Molecular Virology and Recombinant Vaccine Development, Department of Medical Biotechnologies and Translational Medicine, University of Milan, Via Vanvitelli 32, 20129, Milan, Italy. antonia.radaelli@unimi.it.ORCID 0000-0002-5683-6216
Carlo De Giuli Morghen *Catholic University "Our Lady of Good Counsel", Rr. Dritan Hoxha, 123, Tirana, Albania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundZika virus (ZIKV) has been declared a public health emergency that requires development of an effective vaccine, as it might represent an international threat.

methodsHere, two novel DNA-based (pVAXzenv) and fowlpox-based (FPzenv) recombinant putative vaccine candidates were constructed that contained the cPrME genes of ZIKV. The env gene inserted into the fowlpox vector was verified for correct transgene expression by Western blotting and by immunofluorescence in different cell lines. The production of virus-like particles as a result of env gene expression was also demonstrated by electron microscopy. BALB/c mice were immunosuppressed with dexamethasone and immunized following a prime-boost strategy in a heterologous protocol where pVAXzenv was followed by FPzenv, to evaluate the immunogenicity of the Env protein. The mice underwent a challenge with an epidemic ZIKV after the last boost.

resultsThese data show that the ZIKV Env protein was correctly expressed in both normal human lung fibroblasts (MRC-5 cells) and green monkey kidney (Vero) cells infected with FPzenv, and that the transgene expression lasted for more than 2 weeks. After mucosal administration of FPzenv, the immunized mice showed specific and significantly higher humoral responses compared to the control mice. However, virus neutralizing antibodies were not detected using plaque reduction assays.

conclusionsAlthough BALB/c mice appear to be an adequate model for ZIKV infection, as it mimics the natural mild infection in human beings, inadequate immune suppression seemed to occur by dexamethasone and different immune suppression strategies should be applied before challenge to reveal any protection of the mice.

Indexed as

AvipoxvirusGenes, envViral VaccinesZika Virus InfectionAnimalsAntibodies, NeutralizingAntibodies, ViralChlorocebus aethiopsDexamethasoneFibroblastsGene Products, envHumansImmunity, HumoralMiceMice, Inbred BALB CVaccines, SyntheticAntibodies, NeutralizingAntibodies, ViralDexamethasoneGene Products, envVaccines, SyntheticViral VaccinesElectron microscopyFowlpox virusImmune responsePrime–boost vaccinationRecombinant vaccinesZika virus

Identifiers

PMID33663531
PMCPMC7931497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.